drugset / Trial / NCT00384839
Vidaza to Restore Hormone Thx Prostate
Phase 2
Completed
36 enrolled
US Oncology Research
Celgene Corporation · collabUniversity of Southern California · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a bone marrow disease. The pharmaceutical company involved in this study, Pharmion Corporation, is the manufacturer of Vidaza.
Timeline
- Start
- 2006-04
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |